Lincoln Pharmaceuticals Ltd.
-
NSE: LINCOLN
-
BSE: 531633
-
Q
-
V
-
T
Quality Score
High Financial StrengthValuation Score
Affordable ValuationTechnical Score
Technically NeutralTTM PE Ratio
10.50
Below industry Median
Price to Book Ratio
1.50
Below industry Median
Operating Revenues Qtr Cr
112.50 Cr
Above industry Median
Net Profit Qtr Cr
12.60 Cr
Above industry Median
RSI
44.30
RSI is mid-range
MFI
48.70
MFI is mid-range
MACD
-0.60
MACD below Signal and Center
MACD Signal Line
5.70
MACD below Signal and Center
30Day SMA Rs
399.00 Rs
Price below SMA-30
50Day SMA Rs
384.90 Rs
Price below SMA-50
100Day SMA Rs
359.50 Rs
Price above SMA 359.47
200Day SMA Rs
334.50 Rs
Price above SMA 334.47
Promoter holding %
47.00
Promoter holding increased by 0.6600%.
FII holding current Qtr %
1.27
FII holdings fell by 0.17%
MF holding current Qtr %
0.00
MF holding at 0.00%
Institutions holding %
1.27
Institutions holding decreased by 0.1700%.
Broker Covering stock
0.00
0 Broker Covering stock
Broker 1Year total
0.00
0 Broker 1Year total
Broker 6M Reco downgrade
0.00
0 Broker 6M Reco downgrade
Broker 6M Reco upgrade
0.00
0 Broker 6M Reco upgrade
Broker 6M Target downgrade
0.00
0 Broker 6M Target downgrade
Broker 6M Target upgrade
0.00
0 Broker 6M Target upgrade
Momentum score
50.49
Technically Neutral
Valuation score
53.83
Affordable Valuation
Quality score
64.33
High Financial Strength
-
- 2023-05-30T09:21:05+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24 (A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and SEBI Circular No. CIR/CFD/CMDl/27/2019 dated February 08, 2019, we enclosed herewith the annual secretarial compliance report as issued by M/s. Vishwas Sharma & Associates, Practicing Company Secretary (C, P. No. 16942), for the financial year ended on March 31, 2023.
Read More -
- 2023-05-26T11:18:16+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Intimation Of Placing Of The Matter Before The Board Of Directors W.R.T Identification Of Non-Compliance Of Regulation 17(1) Of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('Listing Regulations') And Subsequent Action Taken By The Exchange In The Matter.
Intimation of placing of the matter before the Board of Directors w.r.t Identification of non-compliance of regulation 17(1) of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('Listing Regulations') and subsequent action taken by the exchange in the matter.
Read More -
- 2023-05-26T05:42:39+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclosed herewith the copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2023.
Read More -
- 2023-05-25T12:47:19+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Related Party Transactions For The Half Year Ended On 31.03.2023
Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on 31.03.2023
Read More -
- 2023-05-25T08:29:56+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Dividend Updates
The Board of Directors at their meeting held on today i.e. 25th May, 2023 has recommended dividend of Rs. 1.50/- (i.e 15% per share) per equity share of face value of Rs. 10/- for the year ended 31.03.2023 subject to approval of Members at the ensuing Annual General Meeting of the Company.
Read More -
- 2023-05-25T07:55:59+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2023
FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2023
Read More -
- 2023-05-25T07:04:26+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Change in Directorate
Resignation by Whole Time director is attached herewith.
Read More -
- 2023-05-25T06:18:50+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board approves Dividend
Recommended a Final Dividend of Rs.1.50/- (i.e 15%) per equity shares of face value Rs.10/- each. for the year ended 31.03.2023 for the approval of the members at the ensuring AGM of the Company.
Read More -
- 2023-05-25T06:12:48+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023
FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023
Read More -
- 2023-05-25T06:07:59+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2023
Financial Results (standalone and consolidated) for the Quarter and Year Ended March 31, 2023
Read More -
- 2023-05-16T09:06:24+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and amendments thereof.
Read More -
- 2023-05-15T12:37:42+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board to consider Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 25, 2023, inter alia, to consider and approve the audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2023 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any. Further, in continuation to the Company''s disclosure on closure of trading window dated March 31, 2023, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2023 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.
Read More -
- 2023-05-15T12:31:59+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Inter-Alia To Consider And Approve The Audited (Standalone And Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2023.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2023.
Read More -
- 2023-05-12T10:23:26+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation towards issue of Duplicate Share Certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Read More -
- 2023-05-04T05:31:11+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mahendra Gulabdas Patel & PACs
Read More -
- 2023-04-19T10:04:37+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Certificate Under Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith Certificate from the Practicing Company Secretary under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2023.
Read More -
- 2023-04-15T11:23:29+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyLINCOLN PHARMACEUTICALS LTD. 2CIN NO.L24230GJ1995PLC024288 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: TRUSHA SHAH Designation: COMPANY SECRETARY EmailId: trushashah@lincolnpharma.com Name of the Chief Financial Officer: DARSHIT SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: darshit@lincolnpharma.com Date: 15/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Read More -
- 2023-04-14T12:46:30+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliance Certificate Under Regulation 7 (3) Of SEBI (LODR) For The Period Ended March 31, 2023.
Compliance Certificate under Regulation 7 (3) of SEBI (LODR) Regulations, 2015 for the period ended March 31, 2023.
Read More -
- 2023-04-10T08:33:54+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate as received from M/s. Link Intime India Private Limited, Registrar & Share Transfer Agent (RTA) for the Quarter Ended March 31, 2023.
Read More -
- 2023-03-30T11:26:57+00:00
LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
Intimation of Closure of Trading Window
Read More
| Ex-date | Dividend Amount | Dividend Type | Record Date |
|---|
Bonus History
Adani Ports & Special Economic Zone Ltd. has not announced any bonus since Jan 1, 2000.
Check out stocks with top dividendAdani Ports & Special Economic Zone Ltd. has split the face value 1 time since Sept. 23, 2010. Adani Ports & Special Economic Zone Ltd. had last split the face value of its shares from Rs 10 to Rs 2 in 2016.The share has been quoting on an ex-split basis from Sept. 23, 2010.
| Ex-date | Old FV | New FV | Record Date |
|---|---|---|---|
| Sept. 23, 2010 | 10 | FINAL | Sept. 24, 2010 |